H.C. Wainwright raised the firm’s price target on Apellis Pharmaceuticals to $92 from $82 and keeps a Buy rating on the shares. The firm is increasingly confident that Syfovre is well clear of the “vasculitis phase” and is also increasingly confident that Syfovre can become a blockbuster “sooner rather than later.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on APLS:
- Apellis price target raised to $60 from $39 at Wedbush
- Apellis price target raised to $84 from $70 at Stifel
- Apellis price target raised to $77 from $73 at BofA
- Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
- Apellis reports preliminary FY23 SYFOVRE, EMPAVELI revenue of $366M